ZBH Stock Recent News

Zimmer Biomet, a leader in musculoskeletal health, excels in knee and hip replacements, and surgical robots, making it a sticky choice for many orthopedic surgeons. Competitive advantages include strong surgeon loyalty, technological innovation with the ROSA® Robot, and a global consignment-based distribution model ensuring product availability. Challenges include regulatory hurdles, reliance on elective surgeries, supply chain risks, and fierce competition from companies like Stryker.

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

WARSAW, Ind. , Sept. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that David DeMartino will join the Company as Senior Vice President, Investor Relations, effective September 9, 2024.

Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.

In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.

WARSAW, Ind. , Aug. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will present at two upcoming healthcare conferences in September.

Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.

Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.